INTRODUCTION
Lyme arthritis is a newly recognized epidemic disease that has been occurring at least since 1972 in southeastern Connecticut and other areas bordering Long Island Sound. It is characterized by recurrent attacks of asymmetric large joint arthritis, by geographic and seasonal clustering,and by the presence of a unique preceding skin lesion, erythema chronicuin migrans (ECM)l (1) . Although many patients have had only ECM with or without mild synovitis, others have developed sustained inflammatory joint disease, and some have also had meningoencephalitis, peripheral neuropathy, or cardiac conduction abnormalities (2) . Thus far, efforts to identify a causative agent have been unsuccessful, but epidemiologic studies have indicated transmission by a tick vector (1) (2) (3) (4) . Rheumatoid factor has been absent in virtually all patients.
Synovial biopsy specimens have revealed changes resembling those found in rheumatoid arthritis, including synovial hypertrophy, vascular proliferation, and heavy infiltration with lymphocytes and plasma cells (2) .
These observations suggested that immune complexes might play a role in the pathophysiology of this illness. We postulated that such complexes, if present, might contain antigen(s) related to the elusive causative agent. Furthermore, the seasonal onset and cyclical nature of the illness and the presence of a pre-articular phase (especially ECM) would make it a convenient human model for studying how early immune responses are related to the development of inflammatory joint disease and other clinical events. Consequently, we have looked for evidence of circulating immune complexes in the serum of patients with Lyme arthritis by three standard assay systems: the 125I-Clq binding assay, which detects immune complexes composed of complement-fixing immunoglobulins of any class (6) ; the Clq solid phase assay, which detects immune complexes composed of complement fixing, staphylococcal protein A-reactive IgG (7, 8) ; and the Raji cell assay, which detects immutne complexes that bind to cell surfacee receptors, principally those for C3b an(l C3d (9) .
METHODS
Patients. To compare the results in the three assays for immune complexes, we studied 31 patients with Lyme arthritis who were between the ages of 3 and 67 yr. The clinical features of these patients were described previously (1, 2) . In general, the initial feature of the illness was ECM, wlhich typically lasted for about 3 wk. Approximately 2 wk to 5 mo after the onset of the skin lesion, most patients developed recurrent attacks of arthritis, usually of large joints. Extra-articular complications occurred in three patients. The diagnosis of Lyme arthritis was based on patients having the unique preceding skin lesion of ECM, typical attacks of oligoarthritis, and residency in the endemic area. At each clinic visit, blood to be tested for immune complexes was collected, and on the basis of their history and physical findings, patients were assigned to one of the following categories of disease activity: (a) skin: patients with only ECNI; (b) joints: patients with arthritis; ECM still present or not, hut no other systems involved; (c) heart: patients with cardiac conduction abnormalities, regardless of ECM, arthritis, or peripheral neuropathy; (d) central nervous system: patients with meningitis or meningoencephalitis (documented by abnormal cerebrospinal fluid), regardless of all other feattures; (e) peripheral nervous system: patients with a peripheral neuropathy, without central nervous system or heart involvement, and regardless of skin orjoint involvement; (f) remission: patients with no symptoms or signs for at least 2 wk. To define the relationship of immune complexes to the clinical course of Lyme arthritis, we followed these and an additional 27 patients during various phases of their illness with the 1251-Clq binding assay. For this purpose, when multiple serum samples were taken from individual patients, the results of the first sample obtained during a given phase of the illness was tabulated.
Blood for immume complex assays was drawn in Vacutainer ttubes (Becton, Dickinson & Co., Rutherford, N. J.) and allowed to clot for 1 h at 25°C. After centrifugation the serum was collected, stored in aliquots at -70°C in polypropylene vials (Electro-Sonic Co., Hawthorne, Calif.), and thawed a single time for assay. At the time the assays were performed, the oldest serum had been stored for 10 mo. (13) . The tubes were then incubated at 37°C for 60 min and at 4°C for 30 min, and finally washed three times with cold PBS/tween. The radioactivity that remained bound to the tubes was then measured. The coefficient of variation was 1.9% among duplicates of 50 samples tested on the same day, and 5.8% among positive controls tested on 10 separate days.
The Raji cell assay. The assay was performed in triplicate as described by Theofilopoulos et al (9) . Raji cells (a gift of Doctors Theofilopoulos and Dixon, Scripps Clinic and Research Foundation, La Jolla, Calif.) were grown in Dulbecco's modified minimum essential media (MEM) with 5% fetal calf serum (Grand Island Biological Co., Grand Island, N. Y.). 2 x 106 cells in 20 ,ul of MEM were placed in 1.5-ml microfuge tubes (Beckman Instruments, Inc.) along with 25 ,ul of test serum diluted 1:4 with MEM, and incubated at 37°C for 45 min with gentle agitation at 10-min intervals. Subsequently, the cells were washed three times with MEM, resuspended in 50 ,ul of 1251-rabbit anti-human IgG (labelled by the chloramine-T method) that had been diluted 1:2 with MEM containing 1% rabbit serum albumin (Sigma Chemical Co., St. Louis, Mo.), and then incubated at 40C for 30 min with gentle agitation at 5-min intervals. Finally, the cells were washed three more times with cold MEM containing 1% rabbit serum albumin and the cell-bound radioactivity was measured. The coefficient of variation was 9.8% among triplicates of 30 samples tested on the same day, and 10.5% among positive controls tested on 10 separate days.
Density gradient ultracentrifugation. The relative molecular size and distribution of material reactive in the assays for immune complexes were studied by density gradient ultracentrifugation under two experimental conditions. For the 125I-Clq binding assay, test sera (300 ul) diluted 1:2 with PBS were layered over 4.5 ml, linear, 10-40% sucrose gradients in PBS, and centrifuged at 192,000 g for 14 h in a SW 50.1 rotor (Beckman Instruments, Inc.). In a separate tube, 125I-IgG (7S) and IgM (19S) were used as reference markers. The tubes were punctured and gradient fractions (0.25 ml) were collected from the bottom. The individual fractions were analyzed for immune complexes in the same manner as serum.
For the Clq solid phase and Raji cell assays, 0.25 ml of 1:2 dilutions of test sera were applied to 4.5 ml, linear, 10-37% sucrose gradients in PBS and centrifuged at 222,000 g for 6.2 h in a SW 50.1 rotor. Fractions (0.3 ml) were collected from the top of the gradients by a density gradient fractionator (Instrumentation Specialties Co., Lincoln, Nebr.). 100 ul from each fraction, in the absence of EDTA, was assayed in duplicate for the presence of immune complexes in the Clq solid phase assay, and at a dilution of 1:2 in MEM in the Raji cell assay. The IgG content of the fractions was quantified by a solid phase radioimmunoassay (12) . Sucrose present in the fractions did not interfere with the assays.
Analysis of results. We wished to compare sera from patients with Lyme arthritis directly with sera from normal donors. Consequently, we eliminated the use of standard curves based on the reactivity of aggregated IgG and instead made a direct statistical comparison of the reactivity of normal and test sera. 50 sera from normal donors were surveyed with each assay. Approximately 5% (in the '25I-Clq binding assay and the Raji cell assay) to 10% (in the Clq solid phase assay) were reactive by 2-6 SD above the mean, and these sera were excluded on the grounds that they contained an excess of reactive material, possibly immune complexes. The reactivity of the remaining sera approximated a Gaussian distribution. At the time of each assay, 10 normal sera representative of the larger panel were included with the test sera. The mean and SD of the radioactivity bound in the assays of the normal sera were calculated and the differences in the reactivity of the test sera from the normals were expressed as multiples of this SD. Test sera with reactivity >2 SD above the mean were considered positive.
Detection ofrheumatoid factors. Anti-immunoglobulins of the IgG class were measured by the method of Hay et al. (14) .
Falcon polystyrene tubes (10 x 75 mm) were coated with rabbit IgG (Cappel Laboratories, Inc., Downingtown, Pa.), 10 mg/ liter in PBS for 1 h at 37°C, and then overnight at 4°C. After three washes with PBS, the tubes were incubated for 2 h at room temperature with 1.5 ml of 0.3% gelatin solution in PBS followed by three washes with PBS containing 0.05% tween 20. Test sera were heated at 56°C for 30 min to inactivate complement, and duplicate 50-,lI samples together with 450 Iul of PBS/tween 20 were incubated in the coated tubes for 1 h at 37°C and for 30 min at 4°C. Subsequently, the tubes were washed three times with PBS/tween 20 and bound antiglobulin was detected by the incubation of the tubes with 1 ug of purified (14) heavy-chain specific 125I-rabbit anti-human IgG (Cappel Laboratories, Inc.) at 370C for 1 h and at 4°C for 30 min. The tubes were washed three times with PBS/tween 20, and the radioactivity remaining bound was measured. 10 normal sera, representative of the normal range derived from 50 sera, were included in each assay. Sera from patients with rheumatoid-factor positive rheumatoid arthritis and from sero-negative patients with osteoarthritis were used as positive and negative controls.
The standard latex fixation method (Hyland Diagnostics Div., Travenol Laboratories, Inc., Costa Mesa, Calif.) was used to test sera for 19S-IgM rheumatoid factors (15) .
Complement and cryoglobulin determinations. Total hemolytic complement (CH50) was measured by the method of Kent and Fife (16) and the third (C3) and fourth (C4) components by radial immunodiffusion in Hyland plates (Hyland Diagnostics Div., Travenol Labs., Inc.). Cryoglobulins were measured as described previously (5).
Statistical evaluation. Patient groups were compared by Fisher's exact test. Correlation coefficients (r) were calculated by a standard program in a Hewlett-Packard HP-97 calculator (Hewlett-Packard Co., Palo Alto, Calif.).
RESULTS
Assays for immune complexes. In the initial search for circulating immune complexes, we analyzed 55 sera from 31 patients with active Lyme arthritis or a recent remission, simultaneously in the Clq solid phase assay and in the Raji cell assay and subsequently in the 1251_ Clq binding assay (Table I) . Overall, one or more serum samples from 17 (55%) patients reacted in at least one of the assays. Almost all of the positive reactions occurred with sera from patients having active disease (28/46 active disease sera vs. 1/9 inactive disease sera; P = 0.01). Sera from the two sickest patients-those with cardiac and central nervous system involvement-contained reactive material often at higher levels than in other patients. In contrast, reactive material was found in only approximately onehalf of the sera from patients with arthritis (19 of 35) and rarely in patients during remissions (1 of 9). Two or more sequential samples spanning as many as 9 mo were obtained from 16 patients. Among these samples the results of each assay method tended to remain either consistently positive or negative.
The 125j-Clq binding assay and the Clq solid phase assay results were usually concordant; they were both positive in 20 sera, both negative in 29, and were discordant in only 5 instances. Regression analysis demonstrated a strong positive correlation between the numerical values of these two assays (r = 0.65, P < 0.001). In contrast, positive results were less fre- Density gradient studies. Because it seemed likely that disparate results in the three immune complex assays were the result of the presence either of different types of complexes or of some other reactive material, the assays were applied to a group of sera after sucrose density gradient ultracentrifugation. Initially, the '25I-Clq binding assay was used to compare sera from patients with early mild disease (ECM alone) with those from patients with later, more severe disease (arthritis, meningoencephalitis) (Fig. 2) . In both groups, there were two peaks ofreactivity, one sedimentingjust below the 7S marker and another near the 19S marker. In the patients with only ECM, the two peaks were of approximately equal size, but in the patients with arthritis or meningoencephalitis, the 19S peak predominated. Although the more dense material was compatible with immune complexes, reactivity in the material sedimenting near the 7S marker was more difficult to account for. Immune complexes composed of single IgG molecules and small antigens might have sedimentation coefficients near 7S. However, they would presumably be too small to fix complement and therefore should not react in the assay (17 (Fig. 3) . The Clq solid phase assay detected reactivity in the region of the 19S marker but little or no reactivity over background in the 7S region. Thus, the 7S reactivity in the 125I-Clq binding assay is unlikely to represent IgG-containing material. 7S reactivity in the Raji cell assay was present in sera not only of patients but of normal controls, and paralleled the serum concentration of monomeric IgG. Some patient sera also contained Raji cell reactivity in the 19S region, but it was less prominent than Clq binding in either of the other two assays.
In summary, putative circulating immune complexes in Lyme arthritis sedimented near 19S and reacted equally well in the two Clq assays and less well in the Raji cell assay. A small amount of the reactivity in the 1251-Clq binding assay may be the result of a low density material that does not react in the Clq solid phase assay.
Tests for IgM and IgG rheumatoid factors. Tests for rheumatoid factors by latex agglutination were negative. Nevertheless, we considered the possibility that anti-immunoglobulins of the IgG class might be present and play a role in determining the pattern of Clq-reactive material in the density gradients. However, no evidence for IgG rheumatoid factor was found in 40 sera from patients with Lyme arthritis (Table II) . In contrast, positive results were seen in 15 of 17 sera from patients with rheumatoid arthritis.
Clq reactivity of cryoglobulins. Some serum cryoglobulins contained 1251-Clq-reactive material (Table  III) . Blood from six patients with Lyme arthritis and cryoglobulinemia was allowed to clot at 37°C, and the serum was removed. An aliquot (whole serum) Clq Solid Phase was tested immediately in the i251_Clq binding assay. The remainder was stored at 4°C for 24 h and cryoprecipitable proteins were collected by centrifugation. Both the supernate (serum minus cryoglobulins), and the cryoprecipitable proteinis redissolved in the starting volume ofnormal serum (control serum plus cryoglobulins), were tested. Removal of' cryoprecipitable proteins caused a reduction in the 12I_C1qI binding activity in five of the six sera. In three cases, from sera that had the most Clq binding activity to begin with, the cryoprecipitable proteins transferred Clq reactivity to the normal serum.
Patient studies. We investigated the relationship of circulating immune complexes to the course of Lyme arthritis by following a total of' 58 patients during various phases of their illness, with the 1251-Clq binding assay (Table IV ). 25 patients were tested within the first 3 wk of the appearance of ECM. 20 had only ECM, whereas 5 had some additional complaints of joint discomfort, mainly arthralgias. Among this group, 1251-Clq-reactive material was found in 21 (84%). After ECM disappeared, 9 of 10 patients with nervous system or heart involvement (5 with meningoencephalitis, 3 with cardiac conduction abnormalities, 1 with both, 1 with peripheral neuropathy) had 1251-C lq-reactive material in their blood. In contrast, among 17 patients with attacks of frank arthritis which occurred 4 wk to 18 mo after the skin lesion, 1251-Clq-reactive material (Tables I and IV) , and it often rose and fell in parallel with clinical features of the illness (Fig. 4) . For the most part, it was consistently either present or absent in serial samples from sick individuals (Table I , Fig. 4 ). These findings indicate that reliable measurements of a disease-associated substance -most likely immune complexes-were being made. Many of the clinical and laboratory features of Lyme arthritis are compatible with a pathogenetic role for immune complexes. For example, short attacks of arthritis, peripheral neuropathies, cardiac conduction abnormalities, and involvement of the central nervous system are also features of human serum sickness (18) . Moreover, certain patients with Lyme arthritis have serum cryoimmunoglobulins that contain Clq-reactive material (Table III) ; in those with ECM, the presence of such cryoproteins indicates an increased likelihood that subsequent attacks of arthritis will occur (3) . The fact that serum levels of complement are usually normal or elevated (Fig. 1) may simply indicate that acceleration of complement production during active phases of disease is masking complement consumption. In rheumatoid arthritis, complement levels are usually normal, even when the activated component C3b is elevated in parallel with 125I-Clq binding activity (19) .
Each of the assays used in this study is dependent upon the ability of immune complexes to fix complement. Nevertheless, considerable differences may exist among the assays in the kind of complexes that are detected best, and in the factors that cause interference. The 1251-Clq binding assay can theoretically detect all immune complexes that bind Clq, including those composed of IgM. This advantage is offset to a certain extent by the nonspecific reactivity of Clq with such substances as C-reactive protein, DNA, and endotoxin (20) (21) (22) . In contrast, the Clq solid phase assay is theoretically specific for immune complexes containing immunoglobulin that reacts with both Clq and staphylococcal protein A-mainly IgG1, and IgG2 (23) . Although this assay might fail to detect complexes composed of IgM, IgA, or IgG3, it avoids the possible influence of interfering substances. The Raji cell assay is also subject to a variety of interferences. It detects preferentially the larger complexes formed near antigen-antibody equivalence (9) . Monomeric IgG also binds to these cells, as shown in Fig. 3 . In addition, warm-reactive anti-lymphocyte antibodies might react with the (lymphocytic) Raji cell. Finally, C3b and C3d free in serum can displace immune complexes from the surface of Raji cells, and high levels of these components might cause false-negative reactions (24) .
In the present work there was a remarkable correlation between the two Clq assays (P < 0.001). They each detected reactive material in about 45% of the sera from patients with active disease, and positive and negative results usually agreed (Table I) . It is possible that this figure actually underestimates the true incidence of cirulating immune complexes. The sera that we studied had been collected at 25°C, a temperature at which some cryoprecipitable immune complexes become insoluble (25) . Thus, although the period of serum collection is short (=1 h) and the temperature relatively high (compared to 4°C, as in Table III ), some Clq-reactive material may have been lost.
In contrast to the two Clq assays, the Raji cell assay was positive in only 10 sera (23%). Among these, one reacted strongly and three less so when the other assays were negative. Although the Raji cell and the Clq solid phase assays are about equally sensitive for detecting aggregated IgG (23), we have identified similar discrepancies between the two in patients with disseminated gonococcemia (12) and with glomerulonephritis (23) . These discrepancies may reflect differences in conformation and (or) size among immune complexes, that favor reactivity in one or another system.
The gradient studies demonstrated that reactive substances of two different densities were present in sera from patients with Lyme arthritis (Figs. 2 and 3) . The higher density material sedimenting at approximately 19S is compatible with the circulating immune complexes found in a number of other diseases, including rheumatoid arthritis (6) and cyto-megalovirus infection (26) . Although precise identification of this material will require its isolation, dissociation, and specific reassembly, the fact that it is of high molecular weight, contains IgG, and reacts with Clq suggests that it represents antigen-antibody complexes. Immune complexes of this size are likely to initiate tissue injury (27) , and it may be important that the largest amounts of this material were found in patients with severe clinical manifestations. The high density material was detected best in the assays based on Clq binding; thus, it is not surprising that sera from patients with active disease were more frequently positive in the 1251-Clq binding and the Clq solid phase assays than in the Raji cell assay.
The lower molecular weight material that reacted mainly in the 1251-Clq binding assay may be similar to Clq-reactive, low molecular weight substances found in some patients with systemic lupus erythematosus (28) . Its density and its failure to be detected in the Clq solid phase assay are incompatible with complement fixing immune complexes. Nevertheless, it was not found in sera from normal donors and may be a disease-related substance. Its identification is therefore of interest, and further work is indicated on its specificity and relationship to disease activity.
